Filing summary
Entity note: The supplied filing is GlycoMimetics, Inc.’s Form 10-Q, not a filing for Crescent BioPharma, Inc. It covers the quarter and six months ended June 30, 2022; filed August 3, 2022.
Business context and financial position
GlycoMimetics is a clinical-stage biotechnology company developing glycomimetic drug candidates. It has no approved products and does not generate product-sales revenue. Its lead candidate, uproleselan, is being studied for acute myeloid leukemia (AML).
| Metric | Three months ended June 30, 2022 | Six months ended June 30, 2022 |
|---|---|---|
| Collaboration and license revenue | $75,000 | $75,000 |
| Research and development expense | $7.97 million | $17.58 million |
| General and administrative expense | $5.45 million | $10.51 million |
| Net loss | $13.27 million | $27.92 million |
| Basic and diluted loss per share | $0.25 | $0.53 |
At June 30, 2022, cash and cash equivalents were $60.24 million, down from $90.25 million at December 31, 2021. Total assets were $65.04 million, total liabilities $9.32 million, and accumulated deficit $400.82 million. The filing reports no debt financing; liabilities include operating lease obligations. Current assets were $61.26 million versus current liabilities of $8.94 million. No meaningful product gross margin is reported.
For the six months, operating cash use was $29.93 million, investing cash use $0.08 million, and financing cash flow was zero, versus $9.56 million of financing inflow in the prior-year period. Cash declined by $30.01 million during the first half.
Changes versus prior comparable periods
- Second-quarter revenue rose from $142 in 2021 to $75,000 in 2022. First-half revenue fell 93%, from $1.06 million to $75,000, largely because the prior-year period included clinical-supply revenue from Apollomics; no such supply revenue was recognized in the first half of 2022.
- Second-quarter net loss narrowed 8% to $13.27 million; first-half net loss narrowed 3% to $27.92 million.
- First-half R&D expense declined 18% to $17.58 million, primarily due to lower clinical-development costs following completion of uproleselan trial enrollment and termination of the GMI-1359 trial. Lower stock-based compensation also contributed; higher uproleselan manufacturing and GMI-1687 toxicity-study costs partly offset the decreases.
- First-half G&A expense increased 25% to $10.51 million, driven mainly by commercial start-up and patent costs, along with hiring a Chief Commercial Officer.
- Interest income increased as rates rose. The company implemented a headcount reduction in April 2022, primarily affecting early-stage research and discovery.
Outlook, risks, and other notable matters
- Management expected existing cash to fund operations into the third quarter of 2023, excluding potential financing or business-development proceeds. The filing separately states that substantial doubt exists about the company’s ability to continue as a going concern beyond one year after issuance without additional financing.
- The company had no committed external funding source. It may seek equity or debt financing, collaborations, strategic alliances, or licensing arrangements. A new at-the-market agreement permits up to $100 million in common-stock sales, but no shares had been sold under it through the filing’s issuance date. Financing may be unavailable on acceptable terms and equity issuance could dilute shareholders.
- The global Phase 3 uproleselan trial in relapsed/refractory AML had completed enrollment in 2021. Management anticipated reaching the overall-survival event trigger around mid-2023, with topline results shortly thereafter. COVID-19-related disruption and other clinical-trial uncertainties could affect timing.
- The FDA issued a “safe to proceed” letter in June 2022 for the GMI-1687 investigational application in sickle cell disease; the company was seeking a licensing partner for further development. A planned NCI Phase 2/3 uproleselan trial had completed Phase 2 enrollment; an interim analysis will inform whether it proceeds to Phase 3.
- Apollomics holds Greater China rights to uproleselan and GMI-1687. GlycoMimetics may receive development and commercial milestones and tiered royalties, but timing and achievement are uncertain.
- Nasdaq notified the company on May 31, 2022 that its share price had been below the $1 minimum bid for 30 consecutive business days. The initial compliance period ran through November 28, 2022; failure to regain compliance could lead to delisting and impair liquidity or future fundraising.
- The filing reports no material legal proceedings. Disclosure controls were considered effective as of June 30, 2022, and no material change in internal control over financial reporting was reported for the quarter.
Important facts for investors to verify
- Confirm the issuer identity: the filing is for GlycoMimetics (Nasdaq: GLYC), not Crescent BioPharma.
- Track cash burn, financing progress, and the assumptions underlying the stated runway and going-concern disclosure.
- Verify uproleselan Phase 3 event-trigger timing and subsequent trial results, plus the NCI interim-analysis outcome.
- Monitor Nasdaq bid-price compliance and any use of the $100 million ATM facility, including potential dilution.
- Check whether Apollomics or other partners achieve development milestones or generate supply, royalty, or collaboration revenue.